Góra-Tybor J, Robak T
Zakładu Farmakologii, II Kliniki Chorób Wewnetrznych AM w Lodzi.
Acta Haematol Pol. 1995;26(1):39-45.
Hydroxyurea, an antineoplastic drug evaluated clinically more than 30 years ago, is still the principal drug in patients with myeloproliferative syndromes. It is suggested now that it should be used as initial therapy for chronic myelogenous leukemia. Recently hydroxyurea is used in the treatment of patients with sickle cell disease. It has been shown to augment production of fetal hemoglobin and decrease the propensity of abnormal hemoglobin to polymerize and from the sickle cells in this way.
羟基脲是一种30多年前就已进行临床评估的抗肿瘤药物，至今仍是骨髓增殖性综合征患者的主要用药。目前有人建议，它应用于慢性粒细胞白血病的初始治疗。最近，羟基脲被用于治疗镰状细胞病患者。研究表明，它可增加胎儿血红蛋白的生成，并降低异常血红蛋白聚合的倾向，从而防止镰状细胞的形成。
